Mirati Therapeutics Inc. (NASDAQ:MRTX)‘s stock had its “hold” rating reissued by Leerink Swann in a note issued to investors on Friday. They currently have a $7.00 target price on the stock. Leerink Swann’s price target indicates a potential upside of 18.64% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 6th. Piper Jaffray Cos. restated a “neutral” rating and issued a $7.00 price objective (down previously from $14.00) on shares of Mirati Therapeutics in a report on Monday, August 8th. Finally, Wedbush restated an “outperform” rating and issued a $12.00 price objective on shares of Mirati Therapeutics in a report on Friday, November 4th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Mirati Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.72.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Shares of Mirati Therapeutics (NASDAQ:MRTX) opened at 5.90 on Friday. The company’s market cap is $117.55 million. The company has a 50 day moving average of $5.56 and a 200-day moving average of $7.76. Mirati Therapeutics has a 12-month low of $4.40 and a 12-month high of $40.33.

Large investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP purchased a new stake in Mirati Therapeutics during the third quarter worth approximately $14,999,000. Great Point Partners LLC purchased a new stake in Mirati Therapeutics during the third quarter worth approximately $1,505,000. Tower Research Capital LLC TRC boosted its stake in Mirati Therapeutics by 189.8% in the third quarter. Tower Research Capital LLC TRC now owns 20,214 shares of the company’s stock worth $134,000 after buying an additional 13,240 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Mirati Therapeutics by 1.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 364,284 shares of the company’s stock worth $2,408,000 after buying an additional 6,216 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in Mirati Therapeutics during the second quarter worth approximately $437,000. Hedge funds and other institutional investors own 69.49% of the company’s stock.

5 Day Chart for NASDAQ:MRTX

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.